The Markets

Higher unemployment spurs interest in NZX50

Wednesday 3rd of August 2022

Late yesterday, A2 noted media speculation that it was nearing approval from the US Food and Drug Administration but said its application to sell infant formula in the US was still being reviewed.

The stock, however, added another 0.9% to $5.47 as investors focused on the fact that A2 said it was under “active” review. The stock lifted more than 8% late yesterday on the news...

Want to read the full article?
Click the button below to subscribe and will have unlimited access to full article and all other articles on the site.